NataziaTreatment for Contraception, Heavy Menstrual Bleeding
Update: Natazia (estradiol valerate/dienogest) Now FDA Approved - May 6, 2010
NDA Submitted for estradiol valerate/dienogest Oral Contraceptive
Bayer submits first-in-class estradiol-based oral contraceptive for approval in the U.S.
-- FDA approval requested for oral contraception and treatment of heavy and/or prolonged menstrual bleeding
Berlin, July 8, 2009 - Bayer has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a new estradiol-based oral contraceptive (estradiol valerate/dienogest). It seeks approval for the indications oral contraception and treatment of heavy and/or prolonged menstrual bleeding. The new product with an estradiol valerate/dienogest combination is the first in a new class of oral contraceptives to deliver estradiol, the estrogen identical to the one produced by the female body. It is marketed in Europe under the tradename Qlaira.
"We are pleased to be able to submit the NDA for this new estradiol-based oral contraceptive in the U.S. only a few weeks after Qlaira’s launch in Europe," said Phil Smits, M.D., Head of Women’s Healthcare at Bayer Schering Pharma. "We see a high interest in this new oral contraceptive by women and gynecologists. The NDA underscores the culmination of years of research and development that confirms our goal of developing innovative products that deliver benefits beyond reliable contraception."
Over the past 50 years, many new progestins have been developed for use in oral contraceptives, but the estrogen component remained the same - ethinylestradiol. The new oral contraceptive contains the combination of estradiol valerate - which is immediately metabolized to estradiol, equivalent to the estrogen as produced by a woman’s ovaries - with the progestin dienogest in a unique dosing regimen. This dosing regimen has been designed to deliver hormones at the right levels at the right time during the cycle. If approved by the FDA, the introduction of this new product will offer women a new choice in oral contraception.
An approval for the additional indication - treatment of heavy and/or prolonged menstrual bleeding in the absence of organic pathology in women who desire oral contraception - would represent another important milestone. No other oral contraceptive has yet been approved for treating this condition.
The new oral contraceptive has been available under the tradename Qlaira since May 2009, in several European countries, for the indication oral contraception. Additional European countries will launch Qlaira in autumn 2009 . Bayer is planning to submit the indication heavy and/or prolonged menstrual bleeding in Europe in 2010.
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Bayer Schering Pharma, Consumer Care and Medical Care divisions. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. Find more information at http://www.bayerhealthcare.com.
About Bayer Schering Pharma
Bayer Schering Pharma is a worldwide leading specialty pharmaceutical company. Its research and business activities are focused on the following areas: Diagnostic Imaging, General Medicine, Specialty Medicine and Women's Healthcare. With innovative products, Bayer Schering Pharma aims for leading positions in specialized markets worldwide. Using new ideas, Bayer Schering Pharma aims to make a contribution to medical progress and strives to improve the quality of life. Find more information at http://www.bayerscheringpharma.de.
Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at http://www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Posted: July 2009
- U.S. FDA Approves First and Only Oral Contraceptive Demonstrated to Treat Heavy Menstrual Bleeding (HMB) - March 15, 2012
- FDA Approves Natazia - New Combination Product Oral Contraceptive - May 7, 2010